Radiosynthesis of racemic and enantiomerically pure (-)-[18F]flubatine-A promising PET radiotracer for neuroimaging of α4Β2 nicotinic acetylcholine receptors

Applied Radiation and Isotopes

Volumn 74, Issue , 2013, Pages 128-136

  Fischer, Steffen ^a   Hiller, Achim ^a   Smits, René ^b   Hoepping, Alexander ^b   Funke, Uta ^a   Wenzel, Barbara ^a   Cumming, Paul ^b   Sabri, Osama ^c   Steinbach, Jörg ^a   Brust, Peter ^a  

^a INSTITUTE OF ION BEAM PHYSICS AND MATERIALS RESEARCH   (Germany)

^b ABX Advanced Biochemical Compounds GmbH   (Germany)

^c UNIVERSITY OF LEIPZIG   (Germany)

Author keywords

4 2 nAChR ligands; Fluorine 18; Leaving groups; Neuroimaging; Protecting groups; Radiosynthesis

Indexed keywords

AUTOMATED SYNTHESIS; DEPROTECTION; FLUORINE-18; LABELING EFFICIENCIES; LEAVING GROUPS; NEURODEGENERATIVE DISORDERS; NICOTINIC ACETYLCHOLINE RECEPTORS; NICOTINIC ACETYLCHOLINE RECEPTORS (NACHRS); PROTECTING GROUP; RADIOCHEMICAL PURITY; RADIOFLUORINATION; RADIOSYNTHESIS; SPECIFIC ACTIVITY;

ENANTIOMERS;

NEUROIMAGING;

FLUBATINE F 18; NICOTINIC RECEPTOR ALPHA4BETA2; RADIOPHARMACEUTICAL AGENT; TRIFLUOROMETHANESULFONIC ACID; TRIMETHYLAMMONIUM SALT DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; CATALYST; CHIRALITY; ENANTIOMER; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MOLECULAR IMAGING; NEUROIMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RACEMIC MIXTURE; RADIOACTIVITY; RADIOCHEMISTRY; RADIOFLUORINATION; SYNTHESIS;

BENZAMIDES; BICYCLO COMPOUNDS, HETEROCYCLIC; BRAIN; CHEMISTRY TECHNIQUES, SYNTHETIC; FLUORINE RADIOISOTOPES; HUMANS; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; RECEPTORS, NICOTINIC; STEREOISOMERISM;

EID: 84873934491     PISSN: 09698043     EISSN: 18729800     Source Type: Journal    
DOI: 10.1016/j.apradiso.2013.01.002     Document Type: Article

References (39)

1. Barnes D.E., Yaffe K. The projected effect of risk factor reduction on Alzheimer's disease prevalence. Lancet Neurol. 2011, 10:819-828.
2. Bohnen N.I., Frey K.A. Imaging of cholinergic and monoaminergic neurochemical changes in neurodegenerative disorders. Mol. Imaging Biol. 2007, 9:243-257.
3. 18F]norchloro-fluoro-homoepibatidine. Synapse 2008, 62:205-218.
4. Carpino L.A., Han G.Y. 9-Fluorenylmethoxycarbonyl amino-protecting group. J. Org. Chem. 1972, 37:3404-3409.
5. Carroll F.I. Epibatidine analogs synthesized for characterization of nicotinic pharmacophores-a review. Heterocycles 2009, 79:99-120.
6. Chan W.C., White P.D. Fmoc Solid Phase Peptide Synthesis: A Practical Approach 2000, Oxford University Press, Oxford.
7. Cosgrove K.P., Batis J., Bois F., Maciejewski P.K., Esterlis I., Kloczynski T., Stiklus S., Krishnan-Sarin S., O'Malley S., Perry E., Tamagnan G., Seibyl J.P., Staley J.K. Beta2-nicotinic acetylcholine receptor availability during acute and prolonged abstinence from tobacco smoking. Arch. Gen. Psychiatry 2009, 66:666-676.
8. *-nicotinic acetylcholine receptor availability in smokers with schizophrenia. Am. J. Psychiatry 2012, 169:326-334.
9. Deuther-Conrad W., Patt J.T., Feuerbach D., Wegner F., Brust P., Steinbach J. Norchloro-fluoro-homoepibatidine: specificity to neuronal nicotinic acetylcholine receptor subtypes in vitro. Farmaco 2004, 59:785-792.
10. Deuther-Conrad W., Patt J.T., Lockman P.R., Allen D.D., Patt M., Schildan A., Ganapathy V., Steinbach J., Sabri O., Brust P. Norchloro-fluoro-homoepibatidine (NCFHEB)-a promising radioligand for neuroimaging nicotinic acetylcholine receptors with PET. Eur. Neuropsychopharmacol. 2008, 18:222-229.
11. 18F]N-methyl-NFEP: kinetics, nicotine effect, and toxicity. Nucl. Med. Biol. 1999, 26:139-148.
12. Dollé F. Fluorine-18-labelled pyridines: advances in radiopharmaceutical design. Curr. Pharm. Des. 2005, 11:3221-3235.
13. 18F]fluoropyridin-2-yl)-5'-pyridinyl]-7-azabicyclo-[2.2.1]heptane, a radiolabeled antagonist for cerebral nicotinic acetylcholine receptor (alpha4beta2-nAChR) with optimal positron emission tomography imaging properties. J. Med. Chem. 2008, 51:4751-4764.
14. Green T.W., Wuts P.G.M. Protective Groups in Organic Synthesis 1999, Wiley-Interscience, New York.
15. Gündisch D. Nicotinic acetylcholine receptors and imaging. Curr. Pharm. Des. 2000, 6:1143-1157.
16. 18F]fluoroethyl)-l-tyrosine. Appl. Radiat. Isot. 2002, 57:853-856.
17. 18F]-fluoro-2-deoxy-d-glucose using aminopolyether supported nucleophilic substitution. J. Nucl. Med. 1986, 27:235-238.
18. Hoepping, A., Smits, R., Fischer, S., Hiller, A., Brust, P., Steinbach, J., Patt, M., Patt, J., Sabri, O., 2011. Präkursorverbindungen für die Radiosynthese von [18F]NCFHEB. Patent, DPA Az. 102011052348.0.
19. Horti A.G., Gao Y., Kuwabara H., Dannals R.F. Development of radioligands with optimized imaging properties for quantification of nicotinic acetylcholine receptors by positron emission tomography. Life Sci. 2010, 86:575-584.
20. 11C]methylated analogues of epibatidine as tracers for positron emission tomographic studies of nicotinic acetylcholine receptors. J. Med. Chem. 1998, 41:4199-4206.
21. Horti A.G., Villemagne V.L. The quest for Eldorado: development of radioligands for in vivo imaging of nicotinic acetylcholine receptors in human brain. Curr. Pharm. Des 2006, 12:3877-3900.
22. Irie T., Fukushi K., Ido T., Nozaki T., Kasida Y. F-18-fluorination by crown ether metal fluoride. 2. Non-carrier-added labeling method. Int. J. Appl. Radiat. Isot. 1984, 35:517-520.
23. Jakubke H.-D., Jeschkeit H. Aminosäuren, Peptide, Proteine 1982, Verlag Chemie, Weinheim.
24. 2 nicotinic receptors in the rat brain using microPET imaging. EJNMMI Research 2011, 1:6.
25. * nicotinic acetylcholine receptor availability in patients with mild cognitive impairment and Alzheimer's disease assessed with positron emission tomography. Eur. J. Nucl. Med. Mol. Imaging 2011, 38:515-525.
26. 18F]F-A-85380: PET imaging of brain nicotinic acetylcholine receptors and whole body distribution in humans. FASEB J. 2003, 17:1331-1333.
27. 18F-AZAN, a radioligand with improved brain kinetics. J. Nucl. Med. 2012, 53:121-129.
28. Nordberg A. Nicotinic receptor abnormalities of Alzheimer's disease: therapeutic implications. Biol. Psychiatry 2001, 49:200-210.
29. 123I-5IA-85380 single-photon-emission computed tomography. J. Neurol. Neurosurg. Psychiatry 2007, 878:356-362.
30. 18F-labelling and evaluation of affinity and selectivity at neuronal nicotinic acetylcholine receptors. J Labelled Compd. Radiopharm. 2003, 46(S1). S 168.
31. Pichika R., Easwaramoorthy B., Collins D., Christian B.T., Shi B., Narayanan T.K., Potkin S.G., Mukherjee J. Nicotinic alpha4beta2 receptor imaging agents Part II. Synthesis and biological evaluation of 2-[(18)F]fluoro-3-[2-((S)-3-pyrrolinyl)methoxy]pyridine ((18)F-nifene) in rodents and imaging by PET in nonhuman primate. Nucl. Med. Biol. 2006, 33:295-304.
32. Quik M. Smoking, nicotine and Parkinson's disease. Trends Neurosci. 2004, 27:561-568.
33. Sabbagh M.N., Shah F., Reid R.T., Sue L., Connor D.J., Peterson L.K., Beach T.G. Pathologic and nicotinic receptor binding differences between mild cognitive impairment, Alzheimer disease, and normal aging. Arch. Neurol. 2006, 63:1771-1776.
34. Sabri O., Kendziorra K., Wolf H., Gertz H.J., Brust P. Acetylcholine receptors in dementia and mild cognitive impairment. Eur. J. Nucl. Med. Mol. Imaging 2008, 35(Suppl. 1):S30-S45.
35. *-nicotinic acetylcholinergic receptor dysfunction in major depressive disorder. Am. J. Psychiatry 2012, 169:851-859.
36. Schliebs R., Arendt T. The cholinergic system in aging and neuronal degeneration. Behav. Brain Res. 2011, 221:555-563.
37. 18F]F-A85380: optimized synthesis and in vitro evaluation in Alzheimer's disease. Appl. Radiat. Isot 2004, 61:1235-1240.
38. Spang J.E., Patt J.T., Westera G., Schubiger P.A. Synthesis and [C-11]-radiolabelling of dechloro-epibatidine and 2PABH, two potential radioligands for studying the central nAChRs in vivo. J. Labelled Compd. Radiopharm 1999, 42:761-771.
39. 18F]F2PhEP, two new epibatidine-based radioligands: evaluation for imaging nicotinic acetylcholine receptors in baboon brain. Synapse 2007, 61:764-770.